BIO

Andrew Doyle is the Global Lead for Analytics & Intelligence at Elanco, a leading animal health company spun-out from Eli Lilly in 2019.  He has dedicated his career to harnessing data to tackle the most pressing business challenges related to sales, marketing, and business strategy.  Prior to his role at Elanco, he served as a manager at Deloitte Consulting where he focused on digital and customer transformation within the human healthcare industry.  He graduated with honors from the University of Chicago Booth School of Business, concentrating in marketing and econometrics.